To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy
Cell Stem Cell · 2024
DOI: 10.1016/j.stem.2024.10.009 ↗Kurz gefasst
Kommentar in der Zeitschrift Cell Stem Cell, 2024. Verfasst von S M Yin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences…. Hauptthemen laut MEDLINE: Immunotherapy, Epitopes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yin, S. M., & Li, D. L. (2024). To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy. Cell Stem Cell. https://doi.org/10.1016/j.stem.2024.10.009
Vancouver
Yin SM, Li DL. To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy. Cell Stem Cell. 2024. doi:10.1016/j.stem.2024.10.009
BibTeX
@article{Yin2024,
author = {Yin, S M and Li, D L},
title = {To BE or to PE: Prime editors provide more choices for epitope-editing-based immunotherapy},
journal = {Cell Stem Cell},
year = {2024},
doi = {10.1016/j.stem.2024.10.009}
}
EUVIMED